Published in Lab Business Week, January 30th, 2005
Canvaxin is currently being evaluated in two international, multicenter phase III clinical trials for the treatment of Stage III and Stage IV melanoma.
Under the agreement, CancerVax and Serono will jointly develop Canvaxin for melanoma, as well as other indications. The companies will share equally the costs of developing Canvaxin and seeking regulatory approvals...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.